Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSNeo-DC1.1 in newly diagnosed glioblastoma
NCT07365280Phase 2Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 2, randomised, open-label trial of ZSNeo-DC1.1 in glioblastoma (GBM) (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ZSNeo-DC1.1
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07365280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365280.